BioArctic receives European substance patent for exidavnemab

Stockholm, April 22, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office, EPO, has issued a decision to grant European patent EP4172199B1 for exidavnemab, a drug candidate being developed as a treatment for synucleinopathies such as Parkinson’s disease and Multiple System Atrophy (MSA). The patent enters into force on 14 May 2025 and expires in 2041, with the possibility of extension until 2046.

The release as fetched from its publisher. bioarctic.com ↗